| BORG, Christophe |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
| Not yet recruiting | 3 | 244 | NA | Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group | University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy | Unresectable Metastatic Colorectal Cancer | 10/28 | 10/29 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Recruiting | 3 | 800 | Europe | Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine | UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament | Biliary Tract Neoplasms | 06/27 | 06/28 | | |
REPROGRAM-02, NCT05462613: Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer |
|
|
| Recruiting | 2/3 | 446 | Europe | quality of life questionnaires, Blood sample, Regorafenib, Metronomic chemotherapies, Aspirin, Bevacizumab, FOLFIRI or FOLFOX | Centre Hospitalier Universitaire de Besancon | Metastatic Colorectal Cancer | 11/29 | 11/30 | | |
APACaPOp, NCT03400072: Adapted Physical Activity in Patients With Resected Pancreatic Cancer ( PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial |
|
|
| Recruiting | 2 | 252 | Europe | Unsupervised APA program, Supervised APA program | Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group | Pancreas Cancer, Quality of Life | 02/22 | 08/24 | | |
| Active, not recruiting | 2 | 106 | Europe | Durvalumab, MEDI4736, Tremelimumab, CP-675 | GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca | Advanced Biliary Tract Carcinoma | 07/22 | 12/24 | | |
| Active, not recruiting | 2 | 99 | Europe | MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil | GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG | Anal Cancer | 02/23 | 12/24 | | |
| Completed | 2 | 77 | Europe | DONEPEZIL, PLACEBO | University Hospital, Clermont-Ferrand, Federation Francophone de Cancerologie Digestive | Digestive Oncology, Supportive Care | 01/24 | 01/24 | | |
MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status. |
|
|
| Active, not recruiting | 2 | 307 | Europe | Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan | GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca | Metastatic Pancreatic Adenocarcinoma | 07/23 | 12/24 | | |
SPARTANA, NCT04894370: Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma |
|
|
| Recruiting | 2 | 34 | Europe | Sample collection | Centre Hospitalier Universitaire de Besancon, National Cancer Institute, France, Novartis | Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma | 06/25 | 11/26 | | |
| Active, not recruiting | 2 | 352 | Europe, Canada, US | tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin | Seagen Inc., Genmab, Merck Sharp & Dohme LLC | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck | 02/26 | 11/26 | | |
CLavSyn, NCT03117972: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels |
|
|
| Terminated | 2 | 54 | Europe | FOLFOXIRI, Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, FOLFOX, FOLFIRI, Ironotecan, Bevacizumab, LV5FU2, Capecitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Colorectal Cancer | 08/24 | 11/24 | | |
TEDOPAM, NCT03806309: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | 2 | 106 | Europe | FOLFIRI, Leucovorin (Folinic Acid), Fluorouracil, Irinotecan, OSE2101, Tedopi | GERCOR - Multidisciplinary Oncology Cooperative Group, OSE Immunotherapeutics | Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer | 12/23 | 12/24 | | |
| Active, not recruiting | 2 | 234 | Europe, US, RoW | Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care | Agenus Inc. | Metastatic Colorectal Cancer | 02/25 | 07/25 | | |
ALIX, NCT03974854: Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma |
|
|
| Terminated | 2 | 25 | Europe | XELOXIRI-3, Capecitabine, Oxaliplatine, Irinotecan, Gemcitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Pancreatic Adenocarcinoma | 08/23 | 02/24 | | |
INTERACT-ION, NCT04719988: Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. |
|
|
| Active, not recruiting | 2 | 55 | Europe | Blood sample collection, Biopsy | Centre Hospitalier Universitaire de Besancon, Boehringer Ingelheim | Squamous Cell Carcinoma of the Anus Stage III | 11/24 | 07/26 | | |
CARE, NCT06425133: Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers |
|
|
| Recruiting | 2 | 174 | Europe | Blood sample, Quality of life questionnaires, Biopsy, Regorafenib, Regorafenib + metronomic chemotherapy | Centre Hospitalier Universitaire de Besancon, Groupement Interrégional de Recherche Clinique et d'Innovation | Metastatic Colorectal Cancer | 09/27 | 09/28 | | |
VolATIL, NCT03946358: Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers |
|
|
| Completed | 2 | 47 | Europe | Blood sample collection, Tumor biopsies, CT scan, Atezolizumab, anti-PD-L1, UCPVax, Vaccine | Centre Hospitalier Universitaire de Besancon, Roche Pharma AG, National Cancer Institute, France | Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer | 03/24 | 11/24 | | |
| Recruiting | 2 | 72 | Europe | Nivolumab 10 MG/ML Intravenous Solution, Regorafenib 30 MG Oral Tablet, Radiotherapy, Surgery, Non-operative Management | Jules Bordet Institute | Rectal Cancer Stage II, Rectal Cancer Stage III | 01/26 | 12/30 | | |
FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme |
|
|
| Recruiting | 2 | 400 | Europe | FOLFOX regimen, CAPOX regimen | UNICANCER | Digestive Cancer, Colorectal Cancer | 04/27 | 01/30 | | |
TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer |
|
|
| Not yet recruiting | 2 | 73 | Europe | Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab | UNICANCER, Servier | Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency | 10/26 | 10/28 | | |
TERTIO, NCT05528952: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 105 | Europe | Atezolizumab, Bevacizumab, UCPVax | Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group, PRODIGE | Hepatocellular Carcinoma | 04/25 | 09/27 | | |
LOGICAN, NCT05476796 / 2022-000273-81: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer |
|
|
| Recruiting | 2 | 118 | Europe | Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO | UNICANCER, Servier | Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 01/26 | 01/27 | | |
NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 70 | Europe | Ompenaclid, RGX-202-01, Placebo, Bevacizumab, FOLFIRI regimen | Inspirna, Inc. | Colorectal Cancer, Metastatic Colon Cancer | 09/25 | 12/26 | | |
| Active, not recruiting | 2 | 154 | Europe, Canada, Japan, US, RoW | Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A | GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd | Neoplasms, Rectal | 11/26 | 10/29 | | |
| Recruiting | 2 | 96 | Europe | Nivolumab 480mg + Ipilimumab, Opdivo, Yervoy, Nivolumab 240 mg + Ipilimumab | GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb | Colorectal Cancer Metastatic, MSI-H Colorectal Cancer | 04/27 | 04/28 | | |
TASKIN, NCT05201352: Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine |
|
|
| Recruiting | 1/2 | 160 | Europe | trifluridine/tipiracil + XB2001, trifluridine/tipiracil + placebo | Centre Georges Francois Leclerc | Metastatic Colorectal Cancer | 10/26 | 10/26 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
| Active, not recruiting | 1/2 | 42 | Europe, US | EO4010, Nivolumab, Bevacizumab | Enterome, Enterome SA | Colorectal Cancer Metastatic | 02/26 | 02/26 | | |
Epitopes-CRC01, NCT02838381: Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer |
|
|
| Completed | N/A | 553 | Europe | Additional biological samples | Centre Hospitalier Universitaire de Besancon | Metastatic Cancer | 12/23 | 06/24 | | |
PREDICT-IRFC, NCT04767568: Exploratory Study of the Relevance of a Blood Test in the Management of Patients in the Context of Colorectal Cancer Screening |
|
|
| Recruiting | N/A | 400 | Europe | Blood sample, Tumor tissue, stool collection | Centre Hospitalier Universitaire de Besancon | Colorectal Cancer | 08/25 | 09/28 | | |
Pancreas-CGE, NCT02818907: Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable |
|
|
| Completed | N/A | 290 | Europe | Additional biological samples | Centre Hospitalier Universitaire de Besancon, Cancéropôle Grand-Est | Pancreatic Cancer | 07/23 | 07/23 | | |
NCT06515821: Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods |
|
|
| Recruiting | N/A | 4100 | Europe, RoW | ONCOSCREEN | Firalis SA, University Medical Center Mainz | Colorectal Cancer | 12/26 | 12/26 | | |
HORIZON, NCT06626269: Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies |
|
|
| Not yet recruiting | N/A | 700 | Europe | Blood sample, Tumor tissue | Centre Hospitalier Universitaire de Besancon | Advanced Digestive Cancer, Advanced Gynecologic Cancer | 01/30 | 01/32 | | |
| Recruiting | N/A | 232 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Metastatic Colorectal Cancer, Circulating Tumor DNA | 09/25 | 06/27 | | |
| Recruiting | N/A | 172 | Europe | Blood sampling | Institut Curie | HPV Positive Pelvic Cancer | 06/26 | 06/26 | | |
